Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation
Diagnosed in more than 90% of cervical cancers, the fourth deadliest cancer in women,
human papillomavirus (HPV) is currently the most common pathogen responsible for female …
human papillomavirus (HPV) is currently the most common pathogen responsible for female …
Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination
G Tyros, S Mastraftsi, S Gregoriou… - … journal of STD & …, 2021 - journals.sagepub.com
Anogenital warts (AGWs) rank among the most frequent sexually transmitted infections in
young adults. They are benign lesions, but they pose a significant economic cost to health …
young adults. They are benign lesions, but they pose a significant economic cost to health …
Impact of preventive strategies on HPV-related diseases: ten-year data from the Italian Hospital Admission Registry
Simple Summary HPV-related diseases are mainly represented by cancers. Furthermore,
real world data with respect to the effects of primary and secondary preventive strategies are …
real world data with respect to the effects of primary and secondary preventive strategies are …
Distribution of high-and low-risk human papillomavirus genotypes and their prophylactic vaccination coverage among West African women: systematic review
RA Ouedraogo, A Kande, WMC Nadembega… - Journal of the Egyptian …, 2023 - Springer
Introduction The second most deadly gynecological cancer worldwide, cervical cancer is
steadily on the rise in sub-Saharan Africa, while vaccination programs are struggling to get …
steadily on the rise in sub-Saharan Africa, while vaccination programs are struggling to get …
The effectiveness of a model-based health education program on genital warts preventive behaviors: a quasi-experimental study
Abstract Background Genital warts (GWs) are highly prevalent among Iranian women. GWs
are not only highly infectious but are also followed by severe adverse effects, including the …
are not only highly infectious but are also followed by severe adverse effects, including the …
Evaluation of the optimal sampling approach for HPV genotyping in circumcised heterosexual men with genital warts
M Sarier, N Sepin, M Emek, EY Konuk, T Kaplan… - Journal of Infection and …, 2023 - Elsevier
Background Human papillomavirus (HPV) causes a serious socioeconomic burden globally.
However, there is currently no consensus on the optimal sampling method for HPVDNA …
However, there is currently no consensus on the optimal sampling method for HPVDNA …
HPV 致女性生殖道疾病及HPV 疫苗现况.
罗雅娟， 王丹丹， 杨清 - Journal of International …, 2019 - search.ebscohost.com
人乳头瘤病毒(human papillomavirus, HPV) 是最常见的性传播病毒之一,
在感染女性生殖道后可引起多种病理改变, 其较高的感染率和高致病性严重危害了女性的生殖 …
在感染女性生殖道后可引起多种病理改变, 其较高的感染率和高致病性严重危害了女性的生殖 …
Combination therapy between prophylactic and therapeutic human papillomavirus (HPV) vaccines with special emphasis on implementation of nanotechnology
Human papillomavirus (HPV) is the most prevalent sexually transmitted disease in the world.
Even though preventive vaccines against HPV are effective, the effective treatment of HPV …
Even though preventive vaccines against HPV are effective, the effective treatment of HPV …
A predictive model of genital warts preventive behaviors among women in the south of Iran: application of health belief model
Background Genital wart (GW) is known as an infectious disease. Besides the infection, it is
associated with a higher risk of cervical neoplasia and cancer in the infected population. The …
associated with a higher risk of cervical neoplasia and cancer in the infected population. The …
Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo …
ZJ Mo, ZF Bi, W Sheng, Q Chen, T Huang… - Human Vaccines & …, 2022 - Taylor & Francis
ABSTRACT A dose-escalation, randomized, double-blind, placebo-controlled phase 1
clinical trial enrolled 145 eligible participants aged 18–55 years in March 2015 in Liuzhou …
clinical trial enrolled 145 eligible participants aged 18–55 years in March 2015 in Liuzhou …